27 results
8-K
EX-99.2
TCRX
Tscan Therapeutics Inc
16 Apr 24
TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
4:16pm
with myeloablative (MAC) or reduced intensity conditioning (RIC) between 2017-2019 with 2-year follow-up; MAC relapse range 26-30%, RIC relapse range 38-44% 12 … reached highest dose level AML, MDS, ALL undergoing haploidentical transplant with reduced intensity conditioning Control Arm Treatment Arms Dose Day
8-K
TCRX
Tscan Therapeutics Inc
11 Dec 23
Regulation FD Disclosure
8:00am
”) undergoing haploidentical allogeneic HCT with reduced intensity conditioning. Patients enrolled in Dose Level 1 receive a single dose of either TSC-100
8-K
EX-99.1
TCRX
Tscan Therapeutics Inc
11 Dec 23
Regulation FD Disclosure
8:00am
alone in patients with AML, ALL or MDS undergoing haploidentical allogeneic HCT with reduced intensity conditioning. Patients enrolled in Dose Level 1
8-K
EX-99.2
dubatozxnbgw
11 Dec 23
Regulation FD Disclosure
8:00am
8-K
EX-99.1
hc9f1mh
9 Nov 23
TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
7:15am
424B5
2ik3n
26 May 23
Prospectus supplement for primary offering
8:12pm
424B5
n6iac0q
25 May 23
Prospectus supplement for primary offering
4:59pm
8-K
EX-99.1
nvoeigdde
17 May 23
Poster highlights Phase 1 results following treatment with TSC-100 and TSC-101 after hematopoietic cell transplantation
8:15am
8-K
EX-99.1
7ybks9if4x5d1eilla
9 Nov 22
TScan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
7:06am
8-K
EX-99.1
xcsez iroikcceew6u
10 Aug 22
TScan Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Progress
12:00am
10-K
q282mitjv bp0h7
9 Mar 22
Annual report
7:30am